Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

0
The absurdity of Navarro’s Death by China - Global Times

2018-07-16 globaltimes.cn
Peter Navarro, director of the White House Office of Trade and Manufacturing Policy, is President Donald Trump's stalking horse in a potentially open-ended trade war with China. Armed with a Harvard Ph.D. and academic tenure from the University of California (Irvine), a well-credentialed Navarro was in the right place at the right time to make the leap into the political arena and orchestrate America's increasingly aggressive China bashing strategy.
CICHY MS.PRI MS.PRK MS.PRE MS.PRF MS.PRG MS MS.PRA CICHF CCB 0939

0
Large global investor says its portfolio grew to a record size, but it may slow down investments

2018-07-10 cnbc
Singapore’s state investment firm Temasek Holdings said Tuesday the value of its portfolio jumped above 300 billion Singapore dollars for the first time ever.
CICHY 55BC CBQS CICHF CCB 0939

0
Singapore's Temasek sees slower investments after record portfolio

2018-07-10 malaymail
SINGAPORE, July 10 — Singapore state investor Temasek Holdings' portfolio value hit a record high last year on strong performance in local firms and Chinese banks, but it struck a cautious note by saying it was looking to temper the pace of its investments.
STAN 55BC CBQS CICHY 580001 STAB STAN STAC 2888 SCBFF CICHF CCB 0939

0
Singapore's Temasek sees deals slowing as trade tensions bite

2018-07-10 theedgemarkets
SINGAPORE (July 10): Singapore state investor Temasek Holdings cautioned it was looking to temper its pace of investments this year as trade tensions between world's top two economies ratchet up, after reporting a record high annual portfolio value.
CICHY CICHF CCB 0939

1
China sovereign fund CIC profit soars on record overseas returns

2018-07-09 reuters
SHANGHAI/BEIJING (Reuters) - China’s sovereign wealth fund China Investment Corp (CIC) posted a 37.55 percent rise in 2017 net profit, boosted by record-high returns from its overseas portfolio.
CICHY 55BC TCKRF CBQS CICHF CCB TECK 0939

0
RPT-Singapore's Temasek set to report record portfolio; tech deals in focus

2018-07-08 reuters
SINGAPORE, July 8 (Reuters) - Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion ($221 billion) for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Singapore's Temasek set to report record portfolio; tech deals in focus

2018-07-08 theedgemarkets
SINGAPORE (July 8): Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Singapore’s Temasek set to report record portfolio; tech deals in focus

2018-07-08 malaymail
SINGAPORE, July 8 — Singapore state investor Temasek Holdings Pte Ltd is likely to book a record S$300 billion (RM892.7 billion) for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Singapore's Temasek set to report record portfolio; tech deals in focus

2018-07-08 reuters
SINGAPORE (Reuters) - Singapore state investor Temasek Holdings Pte Ltd [TEM.UL] is likely to book a record S$300 billion ($221 billion) for the value of its portfolio, powered by gains in DBS Group Ltd and Chinese banks, while it steps up investment in tech startups.
CICHY GGRUY 55BC CBQS CICHF GGRUF CCB 0939

0
Hong Kong stocks slammed as investors dump Chinese financials amid trade war anxieties

2018-07-03 scmp
The Shanghai Composite Index drops further after sliding to a 28-month low; the yuan falls to the weakest since last August
CRBJY CICHY 506186 1109 CRBJF GLXYENT CICHF CCB 1088 0939

1013
Weekly Commentary: A Decisive Quarter

2018-06-30 seekingalpha
June 29 - Financial Times (Peter Wells): "The buck is back. Tighter domestic monetary policy and global trade turmoil have set the US dollar for its best quarterly performance since December 2016. The DXY index, which tracks the US currency against a weighted basket of global peers, was up 5.2% in the three months to June 29. That has been achieved via a three-month winning streak, its first such run since December 2016, too.
BBDO CHKVP UAA MS.PRE MS.PRF MS.PRG CHKVZ MS.PRA SCGLF TWTR MS CHK.PRD CICHF CCB SCGLY TYT BDORY CMG BBD VLKAF NDAQ MS.PRI CHK MS.PRK 7203 SFUN GLE FB DB TIF HES TM NFLX AMD CBQS CHKDH CHKDG FMCKI FMCKJ CHKDJ KR ESV CHKDP ACA 0939 CKRGZ FMCCO FMCCP HYUO FMCCM FMCCN 55BC TRIP FMCCI ITUB FMCCJ M FMCCG FMCKO NYTAB FMCKP FMCKM CRARF TOYOF FMCKN FMCKK HYUD FMCKL CHKWZ DO CICHY UA ING OAS FMCC CHK.WI TSLA HYUP CRARY FMCCS FMCCT

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 theedgemarkets
BEIJING (June 27): China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 reuters
BEIJING (Reuters) - China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

2
China's banks embrace Communist Party committees in risk crackdown

2018-06-27 malaymail
BEIJING, June 27 — China’s listed mid-tier and regional banks will face added pressure to curb risky activities following the formal establishment of Communist Party Committees at the lenders, bankers and analysts say.
CGMBF CICHY CHIB CMAKY CICHF CCB CKGOY 0939

4
Can China reduce debt and maintain growth, or is it mission impossible?

2018-06-26 scmp
Releasing funds in response to economic growth headwinds could damage country’s financial situation in long term, analyst says
CICHY IFK IFX 55BC CBQS CICHF CCB 0939

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: Y1397N101